Release of cardiac biomarkers is reported in patientswith subarachnoid hemorrhage (SAH). Data addressing the impact of cardiac injury on outcome in these patients issparse. This study was conducted to ascertain the association of elevation of serum cardiac Troponin-I (cTnI) withmortality and neurological outcome in patients with SAH.Methods
Medical records of all patients admitted with a diagnosisof SAH and at least one measured cTnI were reviewed. Demographic and clinical variables including admission neurologicalstatus were collected. Conservative and non-parametric statistics were used to assess association between cTnI anddeath or neurological outcome at discharge.Results
The study group comprised of 83 patients with a meanage of 59 years. There was a female (60%) and African-American (60%) preponderance. At admission, the median Glasgow Coma Scale (GCS) was 9, and 47% had a severe Hunt–Hess grade (HHG) of ≥4. Elevation of cTnI was found in 31 (37%) patients and was associated with worse baseline Fisher grade (p=0.01) and neurological status: GCS score (p=0.006) and HHG (p=0.007). Patients with abnormal cTnI were more likely to die (55% vs.27%; odds ratio 1.3–8.4, p = 0.01) and had a worse GCS score (p = 0.008) and HHG (p = 0.004) on discharge. On multivariate analysis, peak cTnI (p = 0.04) and admission GCS score of <12 (p = 0.02) were independent predictors of death at discharge.Conclusion
Patients with subarachnoid hemorrhage and elevatedcTnI are found to have worse neurological status at admission. These patients have a worse neurological outcome and in-hospital mortality.